Fidelity Investments’s Oramed Pharmaceuticals ORMP Stock Holding History

Fidelity Investments’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$680	Sell	200 -300	-60%	-$1.02K	﹤0.01%	5134
2025 Q4	$1.43K	Hold	500	–	–	﹤0.01%	5062
2025 Q3	$1.32K	Buy	+500	New	+$1.1K	﹤0.01%	4987
2025 Q1	–	Sell	-1,700	Closed	-$4.11K	–	5586
2024 Q4	$4.11K	Buy	1,700 +200	+13%	+$475	﹤0.01%	4703
2024 Q3	$3.66K	Buy	+1,500	New	+$3.66K	﹤0.01%	4686
2024 Q1	–	Sell	-900	Closed	-$2.08K	–	5607
2023 Q4	$2.08K	Hold	900	–	–	﹤0.01%	4641
2023 Q3	$2.35K	Buy	+900	New	+$2.83K	﹤0.01%	4505
2023 Q2	–	Sell	-1,400	Closed	-$3.05K	–	5536
2023 Q1	$3.05K	Sell	1,400 -36,286	-96%	-$115K	﹤0.01%	4518
2022 Q4	$453K	Hold	37,686	–	–	﹤0.01%	2747
2022 Q3	$244K	Sell	37,686 -46,171	-55%	-$374K	﹤0.01%	2998
2022 Q2	$384K	Buy	83,857 +35,497	+73%	+$190K	﹤0.01%	2928
2022 Q1	$418K	Buy	+48,360	New	+$495K	﹤0.01%	3044

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments's ORMP Position: Q1 2026 in Review

Fidelity Investments reduced its Oramed Pharmaceuticals (ORMP) stake by 60% in Q1 2026, selling an estimated $1.02K and leaving 200 shares worth $680. The position accounts for ﹤0.01% of the portfolio, ranked #5134.

Fidelity Investments first reported a position in ORMP in Q1 2022 and has held it in 12 quarters since. The position peaked at $453K in Q4 2022. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

Fidelity Investments held 200 shares of Oramed Pharmaceuticals worth $680 as of Q1 2026.
Fidelity Investments sold 300 Oramed Pharmaceuticals shares in Q1 2026, an estimated $1.02K.
Oramed Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5134 holding.
Fidelity Investments first reported a position in Oramed Pharmaceuticals in Q1 2022 and has held it in 12 quarters since.
Fidelity Investments's Oramed Pharmaceuticals position peaked at $453K in Q4 2022.
64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.